An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Donald Williams Parsons, Siân Jones, Xiaosong Zhang, Jimmy Lin, Rebecca J. Leary, Philipp Angenendt, Parminder K. Mankoo, Hannah K. Carter, I‐Mei Siu, Gary L. Gallia, Alessandro Olivi, Roger E. McLendon, B. Ahmed Rasheed, Stephen Thomas Keir, Tatiana Nikolskaya, Yuri Nikolsky, Dana Busam, Hanna Tekleab, Luis Alberto Diaz, James Hartigan, Doug R. Smith, Robert L. Strausberg, Suely Kazue Nagahashi Marie, Sueli Mieko Oba‐Shinjo, Hai Yan, Gregory Joseph Riggins, Darell D. Bigner, Rachel Karchin, Giovanni Parmigiani, Bert Vogelstein, Victor E. Velculescu, Kenneth W. Kinzler
Science · 2008 · 5,975 citationsOpen access
No retraction on record in OpenAlex.Check Crossref now
Cite this paper
Parsons, D. W., Jones, S., Zhang, X., Lin, J., Leary, R. J., Angenendt, P., Mankoo, P. K., Carter, H. K., Siu, I., Gallia, G. L., Olivi, A., McLendon, R. E., Rasheed, B. A., Keir, S. T., Nikolskaya, T., Nikolsky, Y., Busam, D., Tekleab, H., Diaz, L. A., … Kinzler, K. W. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321(5897), 1807–1812. https://doi.org/10.1126/science.1164382
In text: (Parsons et al., 2008)
Ask a question about this research
One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.
Abstract
Glioblastoma multiforme (GBM) is the most common and lethal type of brain cancer. To identify the genetic alterations in GBMs, we sequenced 20,661 protein coding genes, determined the presence of amplifications and deletions using high-density oligonucleotide arrays, and performed gene expression analyses using next-generation sequencing technologies in 22 human tumor samples. This comprehensive analysis led to the discovery of a variety of genes that were not known to be altered in GBMs. Most notably, we found recurrent mutations in the active site of isocitrate dehydrogenase 1 (IDH1) in 12% of GBM patients. Mutations in IDH1 occurred in a large fraction of young patients and in most patients with secondary GBMs and were associated with an increase in overall survival. These studies demonstrate the value of unbiased genomic analyses in the characterization of human brain cancer and identify a potentially useful genetic alteration for the classification and targeted therapy of GBMs.
Related papers
- The 2007 WHO Classification of Tumours of the Central Nervous System2007
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary2021
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-20102013
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF12010
- MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma2005
Metadata from OpenAlex (CC0). Citations are generated from the published record.